Meditech begins second stage of Phase II

By Melissa Trudinger
Monday, 06 December, 2004

Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.

The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.

In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.

Content from other channels on our network

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards

Health Star Ratings set to become regulated in Australia and NZ

Fast detection of food contamination using enhanced AI tool

Abattoir safety program in WA raises more awareness

Closing the loop with food packaging made from fish skin waste

Electric trucks hit the road to deliver beer in Perth

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Government seeks input on wind and transmission infrastructure

Additive manufacturing unlocks power for space and defence missions

Meditech begins second stage of Phase II

Noxopharm says paper reveals science behind its immune system platform

Neurosensing/neurostimulation implants session to be held on Monday

argenx and Monash University partner against autoimmune diseases

Content from other channels on our network